Radioligand Therapy Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Radioligand Therapy Market Report 2026

Name: Radioligand Therapy Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Type Of Radioligand (Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions), By Molecular Target (Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets), By Route Of Administration (Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral), By Application (Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases), By End-User (Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings) – Market Size, Trends, Strategies, and Forecast to 2035

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Radioligand Therapy Market Overview

• Radioligand Therapy market size has reached to $6.63 billion in 2025

• Expected to grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10%

• Growth Driver: The Increasing Cancer Incidence Is Fueling The Growth Of The Market Due To Its Rising Prevalence And Demand For Targeted Therapies

• Market Trend: Advancement Of Automated Radioligand Therapy Facilities To Meet Rising Demand

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Radioligand Therapy Market?

Radioligand therapy (RLT) is an advanced form of targeted cancer treatment that links a radioactive isotope to a ligand designed to bind selectively to cancer cell receptors. After administration, it seeks out tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissue. Its targeted approach helps reduce side effects and improves outcomes, particularly in cases resistant to traditional treatments.

The main types of radioligands in radioligand therapy are alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, just a few cell layers, making them highly effective for targeted cell destruction. These radioligands are designed to bind to specific molecular targets such as hormone receptors, growth factor receptors, antigen tumor markers, and others and can be administered through various routes of administration, including intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a range of conditions such as oncological and cardiovascular disorders, neurological disorders, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care setting.

Radioligand Therapy Market Global Report 2026 Market Report bar graph

What Is The Radioligand Therapy Market Size and Share 2026?

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.63 billion in 2025 to $7.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, regulatory approvals for early rlt drugs.

What Is The Radioligand Therapy Market Growth Forecast?

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.

Book your 30 minutes free consultation with our research experts

Global Radioligand Therapy Market Segmentation

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Is The Driver Of The Radioligand Therapy Market?

The increasing cancer incidence is expected to propel the growth of the radioligand therapy market going forward. Cancer is a disease marked by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. Cancer incidence is rising due to long-term exposure to environmental pollutants that damage DNA, disrupt cell function, and promote abnormal cell growth. Radioligand therapy treats cancer by directing radiation to tumor cells through ligands that bind to specific receptors, minimizing harm to healthy tissues and destroying cancer cells internally. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increasing cancer incidence is driving the growth of the radioligand therapy industry.

Key Players In The Global Radioligand Therapy Market

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Global Radioligand Therapy Market Trends and Insights

Major companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to enhance production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers designed to handle and deliver radioactive drugs for targeted cancer treatment using advanced imaging systems and radiation shielding while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Radioligand Therapy Market?

In December 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired POINT Biopharma Global Inc. for $1.4 billion. With this acquisition, Eli Lilly and Company aims to expand its oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment offerings. POINT Biopharma Global Inc. is a US-based pharmaceutical company that specializes in the development of radioligand treatments for cancer.

Regional Insights

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radioligand Therapy Market?

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Radioligand Therapy Market Report 2026?

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Radioligand Therapy Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$7.32 billion
Revenue Forecast In 2035	$10.72 billion
Growth Rate	CAGR of 10.4% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Type Of Radioligand, Molecular Target, Route Of Administration, Application, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Thera
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Radioligand Therapy Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Radioligand Therapy Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Radioligand Therapy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Radioligand Therapy Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Artificial Intelligence & Autonomous Intelligence

4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Targeted Radioligand Therapy For Oncology

4.2.2 Expansion Of Alpha And Beta Emitter-Based Therapies

4.2.3 Integration Of Radioligand Therapy With Personalized Medicine Approaches

4.2.4 Growth In Hospital And Research Institution-Based RLT Programs

4.2.5 Rising Focus On Minimizing Side Effects And Enhancing Patient Outcomes

5. Radioligand Therapy Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Diagnostic Laboratories

5.3 Research Institutions

5.4 Home Care Settings

5.5 Specialty Cancer Centers

6. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Radioligand Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Radioligand Therapy Market Size, Comparisons And Growth Rate Analysis

7.3. Global Radioligand Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Radioligand Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Radioligand Therapy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Radioligand Therapy Market Segmentation

9.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

9.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

9.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

9.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

9.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

9.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

9.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

9.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

9.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

10. Radioligand Therapy Market Regional And Country Analysis

10.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Radioligand Therapy Market

11.1. Asia-Pacific Radioligand Therapy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Radioligand Therapy Market

12.1. China Radioligand Therapy Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Radioligand Therapy Market

13.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Radioligand Therapy Market

14.1. Japan Radioligand Therapy Market Overview

14.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Radioligand Therapy Market

15.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Radioligand Therapy Market

16.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Radioligand Therapy Market

17.1. South Korea Radioligand Therapy Market Overview

17.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Radioligand Therapy Market

18.1. Taiwan Radioligand Therapy Market Overview

18.2. Taiwan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Radioligand Therapy Market

19.1. South East Asia Radioligand Therapy Market Overview

19.2. South East Asia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Radioligand Therapy Market

20.1. Western Europe Radioligand Therapy Market Overview

20.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Radioligand Therapy Market

21.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Radioligand Therapy Market

22.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Radioligand Therapy Market

23.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Radioligand Therapy Market

24.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Radioligand Therapy Market

25.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Radioligand Therapy Market

26.1. Eastern Europe Radioligand Therapy Market Overview

26.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Radioligand Therapy Market

27.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Radioligand Therapy Market

28.1. North America Radioligand Therapy Market Overview

28.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Radioligand Therapy Market

29.1. USA Radioligand Therapy Market Overview

29.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Radioligand Therapy Market

30.1. Canada Radioligand Therapy Market Overview

30.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Radioligand Therapy Market

31.1. South America Radioligand Therapy Market Overview

31.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Radioligand Therapy Market

32.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Radioligand Therapy Market

33.1. Middle East Radioligand Therapy Market Overview

33.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Radioligand Therapy Market

34.1. Africa Radioligand Therapy Market Overview

34.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Radioligand Therapy Market Regulatory and Investment Landscape

36. Radioligand Therapy Market Competitive Landscape And Company Profiles

36.1. Radioligand Therapy Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Radioligand Therapy Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Radioligand Therapy Market Company Profiles

36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Curium LLC Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Telix Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

37. Radioligand Therapy Market Other Major And Innovative Companies

Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

38. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Radioligand Therapy Market

40. Radioligand Therapy Market High Potential Countries, Segments and Strategies

40.1 Radioligand Therapy Market In 2030 - Countries Offering Most New Opportunities

40.2 Radioligand Therapy Market In 2030 - Segments Offering Most New Opportunities

40.3 Radioligand Therapy Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Radioligand Therapy Market, Overview Of Key Products - Product Examples

Table 2: Global Radioligand Therapy Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Radioligand Therapy Market, Supply Chain Analysis

Table 4: Global Radioligand Therapy Market, Major Raw Material Providers

Table 5: Global Radioligand Therapy Market, Major Resource Providers

Table 6: Global Radioligand Therapy Market, Major Manufacturers (Suppliers)

Table 7: Global Radioligand Therapy Market, Major Distributors And Channel Partners

Table 8: Global Radioligand Therapy Market, Key Technologies & Future Trends

Table 9: Global Radioligand Therapy Market, Major Trends

Table 10: Global Radioligand Therapy Market, Major End Users

Table 11: Global Radioligand Therapy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Radioligand Therapy Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Radioligand Therapy Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Radioligand Therapy Market - TAM, US$ Billion, 2025

Table 15: Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Asia-Pacific, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: Asia-Pacific, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: China, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: China, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: India, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: India, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Japan, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Japan, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Australia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Australia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Indonesia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Indonesia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: South Korea, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South Korea, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Taiwan, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Taiwan, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: South East Asia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: South East Asia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Western Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Western Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: UK, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: UK, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: Germany, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Germany, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: France, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: France, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Italy, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Italy, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Spain, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Spain, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Eastern Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Eastern Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Russia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: Russia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: North America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: North America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: USA, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: USA, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: Canada, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Canada, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: South America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: South America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Brazil, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Brazil, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Middle East, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Middle East, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Africa, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Africa, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 98: Global Radioligand Therapy Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 99: Global Radioligand Therapy Market - Company Scoring Matrix

Table 100: Novartis AG Financial Performance

Table 101: Lantheus Holdings Inc. Financial Performance

Table 102: Curium LLC Financial Performance

Table 103: Eckert & Ziegler Strahlen- und Medizintechnik AG Financial Performance

Table 104: Telix Pharmaceuticals Financial Performance

Table 105: Global Radioligand Therapy Market, Competitive Benchmarking (In USD Billions)

Table 106: Global Radioligand Therapy Market, Competitive Dashboard

Table 107: Global Radioligand Therapy Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 108: Global, Radioligand Therapy Market Size Gain ($ Billion), Segmentation By Type Of Radioligand, 2025 – 2030

Table 109: Global, Radioligand Therapy Market Size Gain ($ Billion), Segmentation By Molecular Target, 2025 – 2030

Table 110: Global, Radioligand Therapy Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

List Of Figures

Figure 1: Global Radioligand Therapy Market, Overview Of Key Products - Product Examples

Figure 2: Global Radioligand Therapy Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Radioligand Therapy Market, Supply Chain Analysis

Figure 4: Global Radioligand Therapy Market, Major Raw Material Providers

Figure 5: Global Radioligand Therapy Market, Major Resource Providers

Figure 6: Global Radioligand Therapy Market, Major Manufacturers (Suppliers)

Figure 7: Global Radioligand Therapy Market, Major Distributors And Channel Partners

Figure 8: Global Radioligand Therapy Market, Key Technologies & Future Trends

Figure 9: Global Radioligand Therapy Market, Major Trends

Figure 10: Global Radioligand Therapy Market, Major End Users

Figure 11: Global Radioligand Therapy Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Radioligand Therapy Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Radioligand Therapy Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Radioligand Therapy Market - TAM, US$ Billion, 2025

Figure 15: Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Asia-Pacific, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: Asia-Pacific, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: China, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: China, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: India, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: India, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Japan, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Japan, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Australia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Australia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Indonesia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Indonesia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: South Korea, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South Korea, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Taiwan, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Taiwan, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: South East Asia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: South East Asia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Western Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Western Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: UK, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: UK, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: Germany, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Germany, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: France, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: France, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Italy, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Italy, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Spain, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Spain, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Eastern Europe, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Eastern Europe, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Russia, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: Russia, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: North America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: North America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: USA, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: USA, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: Canada, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Canada, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: South America, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: South America, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Brazil, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Brazil, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Middle East, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Middle East, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Africa, Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Africa, Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 98: Global Radioligand Therapy Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 99: Global Radioligand Therapy Market - Company Scoring Matrix

Figure 100: Novartis AG Financial Performance

Figure 101: Lantheus Holdings Inc. Financial Performance

Figure 102: Curium LLC Financial Performance

Figure 103: Eckert & Ziegler Strahlen- und Medizintechnik AG Financial Performance

Figure 104: Telix Pharmaceuticals Financial Performance

Figure 105: Global Radioligand Therapy Market, Competitive Benchmarking (In USD Billions)

Figure 106: Global Radioligand Therapy Market, Competitive Dashboard

Figure 107: Global Radioligand Therapy Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 108: Global, Radioligand Therapy Market Size Gain ($ Billion), Segmentation By Type Of Radioligand, 2025 – 2030

Figure 109: Global, Radioligand Therapy Market Size Gain ($ Billion), Segmentation By Molecular Target, 2025 – 2030

Figure 110: Global, Radioligand Therapy Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Real Estate Rental Market Report 2026 - Global Outlook – By Type (Residential Buildings And Dwellings Rental Services, Non-Residential Buildings Rental Services, Mini Warehouses and Self-Storage Units Rental Services), B...

Financial Accounting Advisory Services Market Report 2026 - Global Outlook – By Type (Accounting Change Services, Buy-Side Support, Bankruptcy Services, IPO Advisory Services, Financial Reporting Issue And Restatement Se...

Real Estate Agency and Brokerage Market Report 2026 - Global Outlook – By Type (Residential Buildings And Dwellings Brokers, Non-Residential Buildings Brokers, Mini Warehouses And Self-Storage Units Brokers, Other Broker...

Residential Real Estate Market Report 2026 - Global Outlook – By Type (Apartments, Condominiums, Landed Houses, Villas), By Pricing (Affordable, Mid-Range, Luxury), By Size (Less Than 50 Square Meters, 51 To 80 Square Me...

Financial Advisory Market Report 2026 - Global Outlook – By Type (Corporate Finance, Accounting Advisory, Tax Advisory, Transaction Services, Risk Management, Other Types), By Organization Size (Large Enterprises, Small ...

Operations Advisory Market Report 2026 - Global Outlook – By Product Type (Financial Advisory, Technology Advisory, Strategy Advisory, HR Advisory, Manufacturing), By Size (Large Enterprises, Small And Medium Enterprises...

Real Estate Software Market Report 2026 - Global Outlook – By Product (Enterprise Resource Planning (ERP), Property Management System (PMS), Customer Relationship Management (CRM)), By Deployment Type (Cloud, On-Premise)...

Frequently Asked Questions

How big is the Radioligand Therapy Market?

The Radioligand Therapy market was valued at $6.63 billion in 2025, increased to $7.32 billion in 2026, and is projected to reach $10.72 billion by 2030.

What is the Radioligand Therapy market growth?

The global Radioligand Therapy market is expected to grow at a CAGR of 10.0% from 2026 to 2035 to reach $10.72 billion by 2035.

Who are the key players in Radioligand Therapy market?

Some Key Players in the Radioligand Therapy market Include, Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc. .

What is the anticipated growth trend for the Radioligand Therapy market?

Major trend in this market includes: Advancement Of Automated Radioligand Therapy Facilities To Meet Rising Demand. For further insights on this market. request a sample here

Which region has the most growth potential in the Radioligand Therapy market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.